Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
This original research was led by scientists at Revolution Medicines and conducted in collaboration with researchers from across the U.S. and Europe.
- This original research was led by scientists at Revolution Medicines and conducted in collaboration with researchers from across the U.S. and Europe.
- Oncogenic RAS proteins drive up to 30 percent of all human cancers, most notably non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC).
- RAS G12 mutations, such as G12D, G12V and G12C, predominate in human cancers.
- The paper describes the discovery of RMC-6236, an oral, multi-selective inhibitor of the active GTP-bound (ON) state of both mutant and wild-type RAS.